13F filer · CIK 1479355
VHCP Management, LLC
NEW YORK, NY · filing since Q2 2013 · last filing Feb 13, 2017
Reported value
$96.5M
$-18.7M vs prior
Positions
23
New / sold out
2 / 2
Added / reduced
2 / 0
Turnover
5.1%
buys $5.4M · sells $13.2M
Top-10 weight
85.3%
Biggest buys vs Q1 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Adverum Biotechnologies | +1,102,735 | – | +$3.5M |
| Added | BioCryst Pharmaceuticals Inc | +442,161 | +78.5% | +$1.3M |
| Added | Alcobra Ltd | +138,813 | +28.7% | +$623.3K |
| New | Aeglea BioTherapeutics | +6,000 | – | +$29.0K |
Biggest sells vs Q1 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Anacor Pharmaceuticals Inc | -140,756 | -100.0% | $-7.5M |
| Sold out | Avalanche Biotechnologies Inc | -1,102,735 | -100.0% | $-5.7M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2016
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | DBV TechnologiesCOM | 456,893 | $29.1M | 30.17% |
| 2 | Heron Therapeutics IncCOM | 1,095,734 | $19.8M | 20.50% |
| 3 | Coherus Biosciences IncCOM | 611,010 | $10.3M | 10.69% |
| 4 | Flamel Technologies S.A.COM | 500,000 | $5.4M | 5.57% |
| 5 | Zafgen IncCOM | 602,114 | $3.6M | 3.74% |
| 6 | Adverum BiotechnologiesCOM | 1,102,735 | $3.5M | 3.61% |
| 7 | BioCryst Pharmaceuticals IncCOM | 1,005,104 | $2.9M | 2.96% |
| 8 | Alcobra LtdCOM | 623,313 | $2.8M | 2.90% |
| 9 | Lipocine IncCOM | 849,921 | $2.6M | 2.68% |
| 10 | Axovant Sciences LtdCOM | 184,110 | $2.4M | 2.45% |
13 more rows. Subscribe for $29/month to see every row, download the data and use the API.